NextCure (NASDAQ:NXTC) Stock Price Down 2.1% – Here’s What Happened

NextCure, Inc. (NASDAQ:NXTC)’s stock price fell 2.1% during trading on Wednesday . The stock traded as low as $12.97 and last traded at $12.99. 5,523 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 28,493 shares. The stock had previously closed at $13.27.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a report on Friday, October 31st. LADENBURG THALM/SH SH upgraded NextCure from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Friday, November 7th. Finally, Wall Street Zen upgraded NextCure to a “hold” rating in a research note on Saturday, December 13th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

NextCure Stock Performance

The stock has a market cap of $45.59 million, a PE ratio of -0.54 and a beta of 1.52. The company’s 50-day moving average price is $12.34 and its two-hundred day moving average price is $8.48.

NextCure (NASDAQ:NXTC) last announced its earnings results on Wednesday, November 5th. The company reported ($3.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.06) by $0.84. Equities research analysts forecast that NextCure, Inc. will post -1.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NextCure

A hedge fund recently raised its stake in NextCure stock. Cable Car Capital LP increased its position in NextCure, Inc. (NASDAQ:NXTC) by 13.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 758,141 shares of the company’s stock after buying an additional 88,040 shares during the quarter. Cable Car Capital LP owned 28.29% of NextCure worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 42.65% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.